Search clinical trials for: Paliperidone Palmitate

Total 424 results

Janssen-Cilag International NV

Completed

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (CASPAR)

Schizophrenia

Rwanda
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Schizophrenia

Rwanda
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia

Schizophrenia

United States, Belgium, Taiwan, Spain, Israel, Malaysia, South Africa, Korea, Republic of, Slovakia, Croatia, Bulgaria
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Taiwan, Malaysia, Romania, Russian Federation, Serbia, Korea, Republic of
Vir Biotechnology, Inc.
GlaxoSmithKline

Terminated

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

Covid19

United States, France, Ukraine
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Schizophrenia

Poland, United States, Belgium, Taiwan, Spain, Malaysia, Korea, Republic of, Thailand, Slovakia, Croatia
Seoul National University Hospital

Completed

The Effect of Paliperidone Palmitate in Schizophrenia (sustenna)

Schizophrenia

Korea, Republic of
Epirium Bio Inc.

Completed

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

Becker Muscular Dystrophy

United States
Calo Psychiatric Center

Completed

Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment

Schizophrenics
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Schizophrenia

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia

Schizophrenia
Janssen-Cilag Pty Ltd

Completed

Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)

Schizophrenia

Australia
Johnson & Johnson Pte Ltd

Completed

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

Schizophrenia

Australia, China, Hong Kong, Taiwan, Malaysia, Korea, Republic of, New Zealand, Thailand, Philippines
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

Schizophrenia
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Schizoaffective Disorder

United States, Ukraine, Bulgaria, India, Malaysia, Romania, South Africa, Philippines
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia

Schizophrenia

Japan
Janssen Pharmaceutical K.K.

Completed

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pte Ltd

Completed

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia (PREVAIL)

Schizophrenia

China, Taiwan, Malaysia, Korea, Republic of
Janssen-Cilag Farmaceutica Ltda.

Completed

Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate

Schizophrenia

Colombia, Mexico, Brazil
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia

Schizophrenia

Taiwan, Japan, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia

Schizophrenia
Maosheng Fang

Unknown

The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia

Schizophrenia
Janssen Korea, Ltd., Korea

Completed

A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Germany, Spain, India, Russian Federation, Czech Republic, Austria, Hungary, Lithuania, Bulgaria, Estonia, Poland, France
Xian-Janssen Pharmaceutical Ltd.

Completed

A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia

Schizophrenia

China
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Schizophrenia

Japan
Janssen-Cilag International NV

Completed

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics (PROSIPAL)

Schizophrenia

France, Ukraine, United Kingdom, Germany, Taiwan, Spain, Poland, Bulgaria, Romania, Russian Federation, South Africa, Greece, Israel, Korea, Republic of, Belgium, Estonia, Turkey, Czech Republic, Austria, Hungary, Lithuania, Slovakia and more
Luye Pharma Group Ltd.

Completed

Relative Bioavailability of LY03010 Compared to Listed Drug

Mental Disorders | Psychotic Disorders | Mood Disorders | Schizophrenia | Molecular Mechanisms of Pharmacological Action | Tranquilizing Agents | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents | Central Nervous System Depressants | Neurotransmitter Agents | Schizophrenia Spectrum

United States
Ortho-McNeil Janssen Scientific Affairs, LLC

Terminated

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Schizophrenia

United States, China, Colombia, Bulgaria, India, Malaysia, Russian Federation, Ukraine, Canada, Korea, Republic of, Brazil, Czech Republic
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

Schizophrenia (Recent-onset)

United States
Janssen-Cilag Ltd.

Completed

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Schizophrenia

France, Germany, Spain, Israel, Malaysia, Turkey, Taiwan, Greece, Korea, Republic of, Russian Federation, Netherlands, United Kingdom, Croatia, Denmark, Saudi Arabia
Janssen-Cilag International NV

Completed

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Schizophrenia

Germany, Spain, Belgium, Hungary, France, Italy, United Kingdom
Janssen Scientific Affairs, LLC

Completed

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (DREaM)

Psychotic Disorders | Schizophrenia

United States, Brazil, Mexico
UMC Utrecht

Completed

European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)

Schizophrenia

Netherlands, Norway, Austria, Belgium, Bulgaria, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Poland, Romania, Spain, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone

Schizophrenia
Wageningen University
Top Institute Food and Nutrition

Completed

Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO)

Hypertension | Endothelial Dysfunction

Netherlands
Johnson & Johnson Taiwan Ltd

Terminated

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

Schizophrenia

Taiwan
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal (PsiProsper)

Schizophrenia

Portugal
Wei Hao

Completed

An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence

Methamphetamine Dependence

China
Wei Hao

Completed

A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Methamphetamine Dependence

China
Janssen Research & Development, LLC

Completed

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Psychotic Disorders | Schizophrenia | Schizophrenic Disorders | Dementia Praecox

United States, Belgium, Poland, Bulgaria, India, Romania, Russian Federation, Ukraine, Korea, Republic of, Estonia, Finland
Janssen Pharmaceutica

Completed

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag B.V.

Completed

INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

Schizophrenia

Netherlands
Xian-Janssen Pharmaceutical Ltd.

Completed

A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia (PERTAIN)

Schizophrenia

Poland, Israel, Romania, Germany, Lithuania, Croatia, France
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose

Schizophrenia

3

Subscribe